Boston Scientific, Dexcom and Edwards next as earnings season rolls on

J.P. Morgan analysts expect this week’s results to be “very good” following reports from J&J, Abbott and Intuitive Surgical.

By Nick Paul Taylor • April 23, 2024

Intuitive’s rollout of new da Vinci 5 robot steals Q1 spotlight

While Intuitive has already placed eight new surgical robots, executives cautioned system placements could be choppy in the coming months.

By Susan Kelly • April 19, 2024

Abbott looks to ‘highly productive’ device pipeline for future growth

CEO Robert Ford highlighted new and upcoming products throughout the earnings call, calling the recently approved Triclip valve a “billion-dollar opportunity."

By Elise Reuter • April 17, 2024

‘We think in decades’: J&J’s $30B spending spree may not be over

After Johnson & Johnson has doled out more than $30 billion for Abiomed, Laminar and Shockwave Medical, are more medtech deals on the way?

By Ricky Zipp • April 16, 2024

Vicarious presses forward with soft tissue robot despite struggles

The company detailed upcoming milestones for its robotic surgery system on a fourth-quarter earnings call.

By Susan Kelly • March 6, 2024

Medtronic estimates up to 40 job losses in Ireland due to restructuring

The company confirmed the potential job reductions from shutting down its ventilator product lines in an email to MedTech Dive.

By Ricky Zipp • March 5, 2024

Henry Schein expects cyber incident costs to continue in 2024

The company reported a $350 million to $400 million reduction in Q4 sales due to the incident, which forced it to take some systems offline. 

By Elise Reuter • Feb. 27, 2024

Integra Lifesciences to cut about 60 jobs as it closes Indiana site

Manufacturing will be transferred to a plant in Maryland as part of a strategy to bolster operational efficiency, a company spokesperson said.

By Susan Kelly • Feb. 27, 2024

Illumina cut 12% of global staff over past year: CEO

The genomics company, which initiated a fresh round of layoffs last month, expects to finalize its Grail divestiture by the end of June, Jacob Thaysen said Thursday.

By Susan Kelly • Feb. 9, 2024

Zimmer Biomet to cut about 540 jobs

A spokesperson told MedTech Dive that the company will lay off about 3% of its workforce as part of a restructuring. 

By Elise Reuter • Updated Feb. 8, 2024

How Edwards’ Evoque valve won an early nod from the FDA

The heart valve specialist has the chance to shape a new tricuspid market with the first-of-its-kind device, like it did 20 years ago in TAVR, CEO Bernard Zovighian said.

By Susan Kelly • Feb. 7, 2024

Boston Scientific nets Farapulse approval, pushes back US TAVR launch

The device maker disclosed it will start the highly anticipated launch of the AFib ablation device, but approval for its aortic valve replacement implant will have to wait. 

By Susan Kelly • Jan. 31, 2024

The top medtech trends in 2024

Experts said M&A, orthopedic procedure backlogs and emerging cardiac markets were among the top trends to watch in the medical device industry this year.

By MedTech Dive Staff • Jan. 31, 2024

What to watch for as Stryker, Boston Scientific and BD post earnings this week

The next round of results follows reports from J&J, Abbott and Intuitive, all of which signaled a solid end to 2023.

By Nick Paul Taylor • Jan. 29, 2024

Robot reveal: Intuitive submits 510(k) for next-generation system

The new surgical robot will have 10,000 times the processing power of the current da Vinci model, CEO Gary Guthart said on the company’s fourth-quarter earnings call.

By Susan Kelly • Jan. 24, 2024

Abbott says all four segments stronger than pre-pandemic

CEO Robert Ford said investing in its base business using COVID-19 testing revenues was “absolutely the right strategy.”

By Elise Reuter • Jan. 24, 2024

3M on track to complete healthcare spinoff in first half of 2024

The healthcare leadership team will share more details as the completion of the transaction approaches.

By Nick Paul Taylor • Jan. 24, 2024

J&J expects strong procedure volumes in 2024

After reporting growth for its procedure-based units in the fourth quarter, J&J forecast surgery volumes to be above pre-pandemic levels this year.

By Ricky Zipp • Jan. 23, 2024

3 bellwether companies to watch as medtech earnings season begins

J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.

By Nick Paul Taylor • Jan. 22, 2024

Intuitive CEO: Strong robot placements offset bariatric surgery slowdown

Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries.

By Susan Kelly • Jan. 11, 2024

Masimo’s preliminary Q4 results, 2024 outlook exceed analyst expectations

Analysts see the update as evidence Masimo may be rebounding after failing to meet their expectations earlier in the year.

By Nick Paul Taylor • Jan. 11, 2024

5 medtech trends to watch in 2024

From the M&A outlook and tough year-over-year comparisons to emerging markets like pulsed field ablation, here are the top medical technology trends to watch this year.

By Ricky Zipp • Jan. 9, 2024

Edwards to spin off its critical care business

Edwards is the latest healthcare firm to spin off a business to focus on specific markets, following larger companies like Johnson & Johnson and GE.

By Ricky Zipp • Dec. 8, 2023

Roundup: Top medtech companies cut jobs in 2023

Johnson & Johnson, Medtronic and Abbott were among the top companies to announce layoffs this year as the industry implemented cost-cutting measures.

By Ricky Zipp • Nov. 27, 2023

Medtronic CEO downplays the impact of obesity drugs on bariatric surgeries, diabetes unit

The company is the latest medtech to address concerns about how weight loss drugs may impact growth.

By Ricky Zipp • Nov. 21, 2023